GlassScriptPhysician profile
Matthew Colliton
NPI 1609853126
$2,645.80
in general payments reported to CMS, 2019-2025
27 companies · $24.15 in 2025
The $24.15 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,462 · 2020: $278 · 2021: $31.58 · 2022: $106 · 2023: $701 · 2024: $43.90 · 2025: $24.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $676 · Education: $92.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.35 |
| Education | $92.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $325.79 | 2019-2023 | Breztri, Farxiga |
| Novo Nordisk INC | $235.80 | 2019-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $225.23 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $200.69 | 2019-2020 | |
| Amgen INC. | $195.79 | 2019-2023 | Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $184.68 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $153.82 | 2019-2020 | |
| Lilly USA, LLC | $138.39 | 2019-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.48 | 2019-2022 | |
| Amarin Pharma, INC. | $127.71 | 2019 | |
| Glaxosmithkline, LLC. | $125.22 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.52 | 2019-2023 | Xifaxan |
| Abbvie INC. | $74.34 | 2021-2023 | Qulipta, Vraylar |
| Astellas Pharma US INC | $54.68 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $50.38 | 2023 | Rexulti, Jynarque |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $49.29 | 2023-2024 | Dexcom G6 Transmitter |
| Mdd US Operations, LLC | $43.30 | 2019 | |
| Allergan, INC. | $34.98 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $31.55 | 2019 | |
| Lundbeck LLC | $26.94 | 2023 | Rexulti |
| Exact Sciences Corporation | $24.19 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $22.38 | 2023 | |
| Corium, LLC | $20.81 | 2023 | Azstarys |
| Medtronic, INC. | $20.29 | 2023 | Interstim |
| Bausch Health US, LLC | $19.75 | 2023 | Aplenzin, Wellbutrin |
| E.R. Squibb & Sons, L.L.C. | $19.65 | 2024 | Eliquis |
| Circassia INC. | $17.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Colliton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.